ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South Korea
February 26, 2019 17:35 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Feb. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global...
ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines
January 23, 2019 01:35 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI
January 14, 2019 17:44 ET
|
ASLAN Pharmaceuticals Limited
Objective Response Rate of 60% and Disease Control Rate of 100% observed in 300mg dose cohortData demonstrate increased activity of varlitinib in combination with gem/cis compared to standard of care ...
ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer
January 13, 2019 17:30 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Jan. 14, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
Aslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare Conference
November 20, 2018 05:00 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 08, 2018 06:05 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting
November 01, 2018 10:20 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 01, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director
October 30, 2018 03:54 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis
October 17, 2018 12:31 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Oct. 18, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting
September 21, 2018 04:00 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Sept. 21, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...